Nöhles, Viktor B.
Bermpohl, Felix
Falkai, Peter
Reif-Leonhard, Christine
Jessen, Frank
Adli, Mazda
Otte, Christian
Meyer-Lindenberg, Andreas
Bauer, Michael
Rubarth, Kerstin
Anghelescu, Ion-George
Rujescu, Dan
Correll, Christoph U.
Funding for this research was provided by:
Janssen-Cilag GmbH
Charité - Universitätsmedizin Berlin
Article History
Received: 15 June 2023
Accepted: 28 September 2023
First Online: 13 October 2023
Declarations
:
: All methods used in this study are conducted in accordance with relevant guidelines and regulations, including the Declaration of Helsinki, as well as additional clinical, federal state, and national guidelines. Prior to initiating the study, the protocol, patient information and consent form received approval from the Ethics Committees of the Charité – Universitätsmedizin Berlin acting as the coordinating center and from the Ethics Committees of the eight recruitment centers.Each participant in PP2 and PP3 will be thoroughly informed about the study and will provide their written consent. The data gathered in PP1 will be obtained from routine clinical practice and will be anonymized or pseudonymized in accordance with the legal requirements of each state and hospital and will be sent to Charité—Universitätsmedizin Berlin for subsequent analysis.
: Not applicable.
: CU Correll has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Sage, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantic.C Reif-Leonhard has been an advisor to and received speaker honoraria from: Janssen/J&J, LivaNova.C Otte has received honoraria for lectures and/or scientific advice from Boehringer-Ingelheim, Janssen, Limes Klinikgruppe, Lundbeck, Peak Profiling.P Falkai received research support/honoraria for lectures or advisory activities from Boehringer-Ingelheim, Janssen, Lundbeck, Otsuka, Recordati and Richter. IG Anghelescu has been a consultant and/or has received honoraria from Aristo, Janssen, Merck, Recordati, Schwabe. D Rujescu served as consultant for Janssen, received honoraria from Boehringer Ingelheim, Gerot Lannacher, Janssen and Pharmagenetix, received travel support from Angelini and Janssen, and served on advisory boards of AC Immune, Roche and Rovi. M Bauer served as consultant, advisor or speaker for Biogen, Janssen-Cilag, GH Research, Livanova Deutschland GmbH, Novartis, Sunovion, Takeda, neuraxpharm, Shire International GmbH, Aristo, Servier Deutschland GmbH and Hexal AG. F. Jessen has received consulting fees from Eli Lilly, Novartis, Roche, BioGene, MSD, Piramal, Janssen, and Lundbeck. A Meyer-Lindenberg has received consultant fees from Boehringer Ingelheim, Elsevier, Brainsway, Lundbeck Int. Neuroscience Foundation, Lundbeck A/S, Sumitomo Dainippon Pharma Co., Academic Medical Center of the University of Amsterdam, Synapsis Foundation-Alzheimer Research Switzerland, IBS Center for Synaptic Brain Dysfunction, Blueprint Partnership, University of Cambridge, Dt. Zentrum für Neurodegenerative Erkrankungen, Zürich University, Brain Mind Institute, L.E.K. Consulting, ICARE Schizophrenia, Science Advances, Fondation FondaMental, v Behring Röntgen Stiftung, The Wolfson Foundation, and Sage Therapeutics; speaker fees from Lundbeck International Foundation, Paul-Martini-Stiftung, Lilly Deutschland, Atheneum, Fama Public Relations, Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Janssen-Cilag, Hertie Stiftung, Bodelschwingh-Klinik, Pfizer, Atheneum, University of Freiburg, Schizophrenia Academy, Hong Kong Society of Biological Psychiatry, Fama Public Relations, Spanish Society of Psychiatry, Italian Society of Biological Psychiatry, Reunions I Ciencia S.L., and Brain Center Rudolf Magnus UMC Utrecht; awards from the Prix Roger de Spoelberch grant and the CINP Lilly Neuroscience Clinical Research Award 2016. M Adli has received research grants from Servier, Lundbeck, and Gilead; speaker honoraria from Aristo Pharma, Deutsche Bank, HRMForum, Merz Pharma, Gilead, ViiV, MSD, Berlin Chemie, BMS, myTomorrows, Servier, and Lundbeck; and reimbursement of fees and of travel expenses from Lundbeck, Aristo Pharma, and Servier. F Bermpohl, K Rubarth and VB Nöhles have no conflicts of interests to declare.